The ranges of increments were: T: 0.01 -0.16 nglml, A: 0.08 -0.48 ng/ml, P: 0 -1.62 nglml, 17-OHP: 0 -1,61, E2: 0 -18 ~g/ml, F: -35 -+75 nglml. In group 11, the ranges of basal values were: T: 0.05 -0.19 nglml, A: 0.10 -0.62 nglml, P: ND -0.20 nglml, 17-OHP: 0.14 -1.35 ng/ml, E2: 4 -30 ~g / m l and F: 45 -129 nglml.
Again there were significant inc~eases (p<0.025), except for F.
The ranges of increments were: T: 0.09 -0.33 ng/ml, A: 0.14 -1.84 nglml, P: 0 -0.15 nglml, 17-OW: -0.85 -2.04 nglml, E2: 8 -16 pglml, F: -69 -+83 ng/ml.These data give evidence that prepubertal ovary, like prepubertal testis, is easily responsive to hCG. (50)1g/m2 i.v.) prior and after treatment with clomiphene. The boys,mainly those at pubertal stage P3-4 showed definite acceleration of their pubertal process, as judged from the evaluation of pubic hair, testicular volume, penile length and growth velocity. The most consistent laboratory finding was the rise of plasma testosterone , levels (mean +307.8%). The effect on the plasma gonadotrophins was variable. The LH levels rose in 6 boys and the FSH in 5.
LORGITUDINAL STUDY OF THE GONADOTROPHIN RESPONSE TO
There was no correlation between these changes and the testosterone rise and increase in testicular volume; we therefore assume also a direct clomiphene effect on the testes or plasma androgen binding globulin. It seems that clomiphene citrate may be a useful drug to accelerate delayed puberty at stages P3-4 (~anner)or P2 CLaron-Dickerman) . Longitudinal studies are very adequate to detect small individual and significant variations of plasmatic hormons. Thus we performed prolactin determination (PRL) in 12 boys and 9 girls who were patients, in the pediatric department of CHU St-Charles for nonendocrine chronic diseases. PRL determinations were done according to Reuter et al. (1975, Path. Biol. 2, 761-767) using commercial Kits (IRE-Fleury, Belgium) tested in our laboratory for specificity and reproductibility with NIH and MRC standards. In our hands the , I . lntra-assay" error was 5 %, the "inter-assay" error 10 % and the equivalence was found to be 40 pI.U.= I ng NIH, VLS-I. In boys (n = 17) the mean PRL values as a f~~nction of Tanner's puberal stages were found to be (nglml) : We have measured basal, lowest and highest voice frequency (BF, LF,HF), using a simple method, in (1) 372 normal subjects: children and adolescents at ages 6, 8 and 10 years and at the different pubic hair stages (PH), and adults; (2) 71 children with different types of growth failure, and (3) 48 boys with delayed growth and maturation and 31 girls with Turner's syndrome, during fluoxymesterone treatment. BF fell in boys between ages 8 and 10 years (from 259 to 247Hz), but not in girls (253Hz). LF fell between ages 6 and 10 years in boys (from 234 to 203Hz) and girls (from 230 to 218 Hz), and a sex difference appeared. In puberty, a ggadual fall of BF and LF occurred parallel to PH development, both in boys (to 100, 90Hz) and girls (to 213, 180Hz). An abnormally high BF wa's observed in 3 of 12 hyposomatotropic children, 4 of 7 children with Mulibrey nanism, and 2 of 9 children with other prenatal growth failure. Boys with delayed maturation had subnormal BF at PH 1 prior to treatment. At PH 2, fluoxymesterone (0.135mglkglday) treated boys had lower BF than untreated boys. Girls with Turner's syndrome also had slightly subnormal BF for PH after fluoxymesterone (O.lOmg/kg/day). The voice effect was individually variable. In some cases androgen was discontinued because of voice change and a recovery was observed. The method is useful in the clinical characterization of growth failure and stage of puberty. It is particularly recommended for voice monitoring during androgen treatment when a change is undesirable. 56 boys, aged 9.2 -17.8 years, with height deviation for age (HD) (mean+SD) -2.6 i 0.8 SD, lag in Greulich-Pyle bone age (BA) 2.7 i 0.9 years, and height deviation for BA corrected according to a longitudinal Finnish study (IPH, index of potential height) -0.9 f 0.8 SD, were given fluoxymesterone 0.13 i 0.05 mglkg daily (dose increasing with BA) for 1.0 g . 4 years, minimum 0.4 years. Growth velocity during treatment was greater (p<0.001) both in boys with initial BA =10 years (group I, N=16, 7.5 2 0.8 cmlyear) and in boys with initial BA >10 years (group 11, N=40, 9.0 i 1.3 cmlyear) compared with similar control groups (N=15 and 36, velocity 4.1 i 1.4 and 6.1 f 2.1 cmlyear, respectively). AHD was 0.4 + 0.3 SD during treatment against 0.1 ? 0.4 SD in controls (p<0.01). AIPH for group I was -0.4 t 0.6 SD against -0.4 i 0.6 SD in controls, and for group I1 0.2 f 0.3 SD against 0.0 + 0.3 SD in controls (pi0.02). 8 boys of group I and 21 boys of group I1 had a follow-up >0.4 years after treatment and their total AIPH was -0.7 i 1.4 SD and 0.2 + 0.3 SD, respectively. The size of testes clearly increased during treatment in 213 of the boys. Of plasma gonadotrophins FSH decreased from pretreatment levels after 4 -6 months treatment, LH showed no significant change. 3 boys of group I had frequent erections or appearance of pubic hair. Our mode of treatment brings about an acceleration of growth and maturation. In boys with BA >10 years its mean effect on final height is a slight increase. In younger boys this effect is uncertain and it may not be wise to treat boys prior to BA 10 years.
